|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
139,126,000 |
Market
Cap: |
178.08(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.9052 - $5.03 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
31,007 |
35,533 |
57,514 |
116,582 |
Total Sell Value |
$40,857 |
$61,294 |
$139,194 |
$443,003 |
Total People Sold |
4 |
5 |
5 |
9 |
Total Sell Transactions |
8 |
9 |
12 |
23 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klima Thomas J |
See Remarks |
|
2024-03-04 |
4 |
S |
$1.53 |
$6,986 |
D/D |
(4,573) |
124,840 |
|
11% |
|
Obenshain Andrew |
President and CEO |
|
2024-03-04 |
4 |
S |
$1.53 |
$9,311 |
D/D |
(6,095) |
279,998 |
|
11% |
|
Colvin Richard A |
Chief Medical Officer |
|
2024-03-01 |
4 |
S |
$1.53 |
$10,342 |
D/D |
(6,770) |
118,368 |
|
13% |
|
Obenshain Andrew |
President and CEO |
|
2024-02-05 |
4 |
S |
$0.90 |
$1,696 |
D/D |
(1,879) |
286,093 |
|
-51% |
|
Vittiglio Joseph |
Chief Business & Legal Officer |
|
2024-02-05 |
4 |
S |
$0.90 |
$4,708 |
D/D |
(5,217) |
44,783 |
|
-51% |
|
Klima Thomas J |
See Remarks |
|
2024-02-05 |
4 |
S |
$0.90 |
$2,449 |
D/D |
(2,714) |
129,413 |
|
-51% |
|
Colvin Richard A |
Chief Medical Officer |
|
2024-01-05 |
4 |
S |
$1.42 |
$845 |
D/D |
(597) |
125,138 |
|
4% |
|
Obenshain Andrew |
President and CEO |
|
2024-01-05 |
4 |
S |
$1.43 |
$4,520 |
D/D |
(3,162) |
287,972 |
|
4% |
|
Krawtschuk Christopher |
Chief Financial Officer |
|
2023-12-06 |
4 |
S |
$4.52 |
$20,437 |
D/D |
(4,526) |
45,474 |
|
72% |
|
Klima Thomas J |
See Remarks |
|
2023-09-05 |
4 |
S |
$3.79 |
$3,493 |
D/D |
(922) |
132,127 |
|
60% |
|
Obenshain Andrew |
President and CEO |
|
2023-08-10 |
4 |
S |
$3.54 |
$59,956 |
D/D |
(16,929) |
291,941 |
|
10% |
|
Klima Thomas J |
See Remarks |
|
2023-06-02 |
4 |
S |
$3.50 |
$14,451 |
D/D |
(4,130) |
133,049 |
|
21% |
|
Paulson Richard A. |
|
|
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,663 |
4,663 |
|
- |
|
Klima Thomas J |
See Remarks |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
137,179 |
|
- |
|
Colvin Richard A |
Chief Medical Officer |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
128,078 |
|
- |
|
Obenshain Andrew |
President and CEO |
|
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
67,600 |
308,870 |
|
- |
|
Colvin Richard A |
Chief Medical Officer |
|
2023-02-01 |
4 |
D |
$6.38 |
$7,356 |
D/D |
(1,153) |
73,078 |
|
- |
|
Obenshain Andrew |
President and CEO |
|
2023-02-01 |
4 |
D |
$6.38 |
$9,060 |
D/D |
(1,420) |
241,270 |
|
- |
|
Klima Thomas J |
See Remarks |
|
2023-02-01 |
4 |
D |
$6.38 |
$14,419 |
D/D |
(2,260) |
82,179 |
|
- |
|
Vittiglio Joseph |
Chief Business & Legal Officer |
|
2023-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Colvin Richard A |
Chief Medical Officer |
|
2023-01-11 |
4 |
S |
$7.80 |
$4,347 |
D/D |
(557) |
74,231 |
|
53% |
|
Leschly Nick |
|
|
2023-01-11 |
4 |
S |
$7.80 |
$33,480 |
D/D |
(4,290) |
280,149 |
|
53% |
|
Obenshain Andrew |
President and CEO |
|
2023-01-11 |
4 |
S |
$7.80 |
$24,802 |
D/D |
(3,178) |
242,690 |
|
53% |
|
Krawtschuk Christopher |
Chief Financial Officer |
|
2022-12-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Obenshain Andrew |
President and CEO |
|
2022-11-04 |
4 |
S |
$6.41 |
$8,101 |
D/D |
(1,263) |
245,868 |
|
27% |
|
939 Records found
|
|
Page 1 of 38 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|